Chromium: Benefits, Forms, Dosing, and Side Effects

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• Frequently Asked Questions
• References

Overview

Chromium is an essential trace mineral required in small amounts for normal human metabolism. In its trivalent (+3) form, chromium plays a role in carbohydrate, lipid, and protein metabolism by potentiating insulin action [1][2][3]. The precise mechanism by which chromium exerts these effects has not been fully elucidated, but the prevailing hypothesis is that chromium binds to an oligopeptide called chromodulin (also known as low-molecular-weight chromium-binding substance, or LMWCr), which in turn binds to and activates the insulin receptor, amplifying downstream signaling including increased tyrosine kinase activity and enhanced glucose uptake into cells [1][3][4][5]. Chromium may also have antioxidant effects [1].

It is important to distinguish trivalent chromium (+3), the form found in food and supplements, from hexavalent chromium (+6), which is a toxic industrial by-product classified as a Group 1 carcinogen by the International Agency for Research on Cancer [1][6]. This article focuses entirely on trivalent chromium.

Essential Nutrient or Not?

The question of whether chromium is truly "essential" is more contested than for most trace minerals. In 2001, the Food and Nutrition Board (FNB) of the National Academies considered chromium essential based on its effects on insulin action and established Adequate Intake (AI) levels [2]. However, subsequent research has challenged this classification. In 2014, the European Food Safety Authority (EFSA) concluded that no convincing evidence shows chromium is an essential nutrient and deemed it inappropriate to set chromium intake recommendations [7]. The debate centers on the fact that no clearly defined chromium deficiency state has been established in healthy populations, and the original case reports of "chromium deficiency" in patients on total parenteral nutrition (TPN) have been re-evaluated and found to not provide convincing evidence of true deficiency [1][3][7][8][9].

In three case studies published in the 1970s and 1980s, patients on long-term TPN experienced adverse metabolic and neurological effects, including hyperglycemia, glycosuria, unexplained weight loss, peripheral neuropathy, glucose intolerance, and confusion [10][11][12]. These effects were alleviated with pharmacologic amounts of chromium and were originally presumed to be caused by chromium deficiency. However, the studies did not adequately evaluate chromium concentrations in the TPN solutions, and scientists have concluded based on recent evaluations that these cases do not demonstrate that healthy people can develop chromium deficiency [3][7][8][9].

Currently, chromium is routinely added to TPN solutions at 10–15 mcg/day, which is much higher than the approximately 0.15 mcg/day that healthy individuals absorb from a balanced diet. The American Society for Parenteral and Enteral Nutrition has recommended research to determine whether these levels should be lowered [9][13][14].

Despite this controversy, chromium remains widely included in multivitamin/mineral supplements. Most multivitamins contain 35–120 mcg of chromium, and standalone supplements commonly provide 200–1,000 mcg [15].

Absorption and Status Assessment

In the blood, most chromium is bound to plasma proteins, particularly transferrin, with only about 5% unbound [7][16]. Chromium accumulates mainly in the liver, spleen, soft tissue, and bone [2][7][16].

Dietary chromium absorption is remarkably low, typically ranging from only 0.4% to 2.5% of ingested amounts [7][17]. The absorption of various supplemental forms is broadly similar: chromium picolinate is absorbed at approximately 1.2%, while chromium chloride is absorbed at approximately 0.4% [1]. These values are comparable to the proportion of chromium absorbed from food [7]. Absorption is enhanced by ascorbic acid (vitamin C) and prostaglandin inhibitors such as aspirin, and inhibited by oxalate, phytates, and antacids [1][18].

Chromium is excreted mainly in the urine [1][16]. Urinary chromium levels reflect recent intake but are not reliable indicators of body stores [3][19]. Hair levels might reflect past chromium intakes [7], and some studies have measured chromium levels in hair, sweat, serum, and toenails [19][20]. However, no validated method for determining chromium status exists, and no clinically defined chromium deficiency state has been established in healthy populations [3][17].

Historical Context: The "Glucose Tolerance Factor"

In the past, some chromium products used the term "GTF" (glucose tolerance factor) in their names. Based on research from several decades ago, scientists hypothesized that the body combined chromium with nicotinate and other substances to form a large molecule called GTF that helped control blood sugar. Certain foods, such as brewer's yeast, were thought to contain pre-formed GTF, and products containing chromium polynicotinate or brewer's yeast extracts sometimes used "GTF" in their labeling [21]. However, it is now believed that GTF does not actually exist as originally described; the substance appears to have been inadvertently produced by chemists during their attempts to study chromium's effects [21]. Current thinking attributes chromium's biological activity to chromodulin (LMWCr) rather than GTF [4][5].

Forms and Bioavailability

Several forms of chromium are available as dietary supplements. The choice of form affects absorption, tolerability, and cost, though differences between forms are less dramatic than with some other minerals.

Comparison Table

Form	Elemental Cr (%)	Absorption (%)	Key Characteristics
Chromium Picolinate	12.4%	~1.2%	Most studied form. Chromium bound to picolinic acid. Better absorbed than chromium chloride. Used in most diabetes and weight loss trials. Theoretical safety concerns raised but not substantiated [1][15][22].
Chromium Polynicotinate	Variable	Similar to picolinate	Chromium bound to nicotinic acid (niacin). Sometimes marketed as "niacin-bound chromium." Better absorbed than chromium chloride [21][23].
Chromium Chloride	N/A	~0.4%	Inorganic salt. The least bioavailable supplemental form. Used in some older clinical trials [1][21].
Chromium Glycinate	Variable	Enhanced vs chloride	Chromium chelated to glycine. Glycinate chelation improves bioavailability compared to inorganic forms (approximately 43% higher absorption demonstrated for glycinate mineral chelates generally) [24].
High-Chromium Yeast	Variable	Variable	Brewer's yeast naturally contains chromium bound to organic compounds. Historically associated with "GTF." Absorption and chromium content vary by product [21][23].
Chromium Histidinate	Variable	Similar to picolinate	Chromium bound to histidine. Limited comparative data. Absorption appears comparable to other organic forms [19].

Key Principles for Form Selection

Organic forms are better absorbed than inorganic forms. Chromium picolinate and chromium polynicotinate are both better absorbed than chromium chloride [21]. However, the absolute absorption of all forms remains low (generally 0.4–2.5%) [7][17].

The elemental chromium content matters. Chromium picolinate, for example, is only 12.4% elemental chromium by weight [15][22]. The Supplement Facts label on a dietary supplement product declares the amount of elemental chromium, not the weight of the entire chromium compound [15].

Chromium picolinate has the most clinical trial data. The majority of intervention studies on diabetes, weight, PCOS, and lipids have used chromium picolinate, making it the most evidence-backed form [1][15][23].

Glycinate chelation offers enhanced bioavailability. Glycinate forms of trace minerals generally demonstrate approximately 43% higher bioavailability compared to cheaper gluconate or inorganic forms [24]. Dr Brad Stanfield's MicroVitamin includes 17.5 mcg of chromium in the glycinate form, chosen specifically for this bioavailability advantage.

Safety concerns about chromium picolinate have not been substantiated. Two preliminary studies suggested chromium picolinate might damage DNA in vitro [25][26], and because picolinic acid might affect neurotransmitter levels, caution has been advised in people with depression, bipolar disease, or psychosis [21]. However, no adverse effects from chromium picolinate have been confirmed in human studies at standard supplemental doses [1][21].

Evidence for Benefits

Type 2 Diabetes and Blood Sugar Control

The most studied application of chromium supplementation is for blood sugar management in people with type 2 diabetes. The evidence is substantial but mixed, with the weight of evidence suggesting a modest benefit primarily in those with poor glycemic control.

The landmark 1997 Chinese trial. The most commonly cited intervention study assigned 180 adults aged 35–65 with type 2 diabetes to receive 100 mcg chromium (as chromium picolinate), 500 mcg chromium, or placebo twice daily for 4 months. At both 2 and 4 months, participants receiving 1,000 mcg/day had significantly lower fasting glucose (mean 7.1 mmol/L [128 mg/dL] vs 8.8 mmol/L [159 mg/dL] for placebo at 4 months), lower post-glucose-challenge levels (10.5 mmol/L [189 mg/dL] vs 12.3 mmol/L [222 mg/dL]), and lower HbA1c (6.6% vs 8.5%). Both 200 mcg and 1,000 mcg/day also significantly reduced fasting and post-challenge insulin concentrations (Anderson et al., Diabetes, 1997) [27].

Brazilian trial (poorly controlled T2D). A study among 71 men and women with poorly controlled type 2 diabetes taking antidiabetes medications (biguanides and sulfonylureas) found that 600 mcg of chromium picolinate daily (300 mcg after breakfast and dinner) for 4 months significantly reduced fasting blood sugar (−31 mg/dL vs −14 mg/dL), postprandial blood sugar (−37 mg/dL vs −11.5 mg/dL), and HbA1c (−1.9% vs −1.0%) compared to placebo (Paiva et al., J Trace Elem Med Biol, 2015) [28].

Dutch trial (negative result). A study among 46 men and women with poorly controlled type 2 diabetes taking insulin found no benefit from either 250 mcg or 500 mcg of chromium picolinate taken twice daily with meals for 6 months compared to placebo (Kleefstra et al., Diabetes Care, 2006) [29].

Australian trial (negative result). A randomized, placebo-controlled, double-blind trial of chromium supplementation in subjects with impaired glucose tolerance found that chromium supplementation did not improve glucose tolerance, insulin sensitivity, or lipid profiles (Gunton et al., Diabetes Care, 2005) [30].

Characterization of responders. A randomized trial in 137 participants aged 30–70 with type 2 diabetes found that 1,000 mcg of chromium picolinate daily for 24 weeks did not significantly affect insulin sensitivity, fasting glucose, or HbA1c overall. However, some participants did respond, and these "responders" had significantly lower baseline insulin sensitivity (3.98 vs 5.91 mg/kg fat-free mass/min), higher fasting glucose (8.5 vs 6.7 mmol/L [153 vs 121 mg/dL]), and higher HbA1c (7.57% vs 6.29%) than non-responders. This suggests chromium may be more likely to benefit those with more severe insulin resistance and poorer glycemic control (Cefalu et al., Metabolism, 2010) [31].

Comprehensive review of 8 meta-analyses (58 clinical trials). A 2019 review examined the totality of evidence from 58 clinical trials lasting 3 weeks to 6 months using 1.28 to 1,000 mcg chromium daily. The most frequently used form was chromium picolinate, followed by chromium-enriched yeasts and chromium chloride. Overall, when used as adjuvant treatment, chromium lowered fasting plasma glucose and HbA1c levels slightly in people with diabetes. However, the clinical significance of these improvements was unclear. The authors noted that chromium supplements do not help moderate glucose levels in healthy individuals (Costello et al., Nutr Rev, 2016) [32][33].

Systematic review of 41 clinical studies. This review concluded that chromium supplementation may have a "modest beneficial effect" in people with type 2 diabetes. On average, chromium picolinate supplementation lowered HbA1c by 0.6%, and brewer's yeast and chromium picolinate lowered fasting glucose by 1.1 and 0.8 mmol/L, respectively. These effects were not found in people without diabetes (Balk et al., Diabetes Care, 2007) [34].

FDA qualified health claim. Based on the evidence, the FDA allows only the following carefully qualified statement: "One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain" [39][40].

American Diabetes Association position. In its 2010 guidelines, the ADA concluded that studies have not definitively shown that chromium supplementation benefits people with diabetes or obesity, and therefore the association cannot recommend such supplementation [41]. This was reinforced in its 2015 position statement [42].

Synthesis. Chromium supplementation, primarily as chromium picolinate at doses of 200–1,000 mcg/day, may produce modest reductions in fasting glucose and HbA1c in some people with type 2 diabetes, particularly those with poor glycemic control and greater insulin resistance. The effect size is small (HbA1c reduction approximately 0.6% on average), the evidence quality is mixed, and the clinical significance remains debated. Chromium does not appear to benefit blood sugar in healthy, non-diabetic individuals.

Reactive Hypoglycemia

A small study found that 200 mcg of chromium chloride daily for 3 months improved symptoms and increased blood glucose levels in patients with reactive hypoglycemia (Anderson et al., Metabolism, 1987) [43]. This remains the only published trial on this specific indication, and the evidence should be considered preliminary.

Insulin Sensitivity in Non-Diabetic Individuals

An important study examined whether chromium supplementation might benefit healthy individuals. People who were neither obese nor diabetic received 1,000 mcg of chromium daily (500 mcg twice daily from chromium picolinate) or placebo for 16 weeks. The supplement did not improve insulin sensitivity, lipid levels, or waist fat. Disturbingly, participants who achieved the highest blood serum chromium levels (above 3.1 mcg/L) experienced a worsening of insulin sensitivity (Masharani et al., BMC Endocrine Disorders, 2012) [44]. This finding raises concerns about potential harm from high-dose chromium supplementation in people who are not chromium deficient and do not have diabetes.

Metabolic Syndrome

Metabolic syndrome is a cluster of risk factors — abdominal obesity, high triglycerides, low HDL cholesterol, hypertension, and elevated fasting glucose — that raises the risk of heart disease, diabetes, and stroke [45]. Because insulin resistance is central to this condition, researchers have investigated whether chromium might help.

Prospective epidemiological data. A study of 3,648 adults aged 20–32 found that baseline toenail chromium concentrations were inversely associated with the incidence of metabolic syndrome over 23 years of follow-up (Bai et al., Sci Rep, 2015) [46].

Clinical trial (500 mcg twice daily). A trial of 63 adults aged 18–75 with metabolic syndrome who received 500 mcg chromium picolinate or placebo twice daily for 16 weeks found that chromium significantly increased acute insulin response to glucose but did not affect HbA1c, insulin sensitivity, or other glucose metabolism measures. Chromium also had no effect on body weight or serum lipids (Iqbal et al., Metab Syndr Relat Disord, 2009) [47].

Chromium yeast trial. A 2018 trial of 70 adults (mean age 58) with metabolic syndrome and impaired glucose tolerance found that 300 mcg chromium daily (as chromium yeast) for 24 weeks did not affect fasting glucose, HbA1c, waist circumference, blood pressure, or lipid levels (Nussbaumerova et al., Biol Trace Elem Res, 2018) [48].

Synthesis. Limited research suggests that chromium supplements do not significantly benefit people with metabolic syndrome, despite the condition's association with insulin resistance.

Polycystic Ovary Syndrome (PCOS)

PCOS is a common endocrine disorder affecting women of reproductive age, characterized by infertility, obesity, dyslipidemia, hyperandrogenism, and elevated risks of type 2 diabetes and cardiovascular disease [50][51]. Because insulin resistance is often central to PCOS, chromium supplementation has been studied for this population.

Meta-analysis of 7 trials (n=351). An analysis of seven trials administering chromium picolinate at 200–1,000 mcg daily for 8–24 weeks found no effect on fasting blood glucose, total testosterone, dehydroepiandrosterone, follicle-stimulating hormone, or luteinizing hormone. However, chromium did significantly reduce BMI by 2.37 kg/m² and free testosterone by 0.52 pg/mL, and reduced fasting insulin by 0.33 milli-IU/mL (Fazelian et al., J Trace Elem Med Biol, 2017) [51].

Systematic review of 5 trials (n=268). A review comparing 200–1,000 mcg/day chromium with placebo or metformin found no significant effect on fasting insulin or insulin sensitivity, but data from two trials showed chromium significantly lowered a measure of insulin resistance. The authors concluded the magnitude of effect was small and of uncertain clinical relevance (Tang et al., J Obstet Gynaecol Res, 2018) [52].

Additional meta-analyses. Two further systematic reviews had similarly mixed findings. Heshmati et al. (2018) found some improvements in HOMA-IR but inconsistent effects across studies [53]. Maleki et al. (2018) concluded that chromium does not improve weight loss or metabolic and hormonal variables in PCOS [54].

Synthesis. The evidence on chromium for PCOS is mixed. There are signals of modest benefit for reducing BMI, free testosterone, fasting insulin, and insulin resistance, but the effects are small and clinical significance is uncertain.

Dyslipidemia (Cholesterol and Triglycerides)

Numerous studies have found associations between poor chromium status and elevated blood cholesterol levels, prompting research into supplementation [23].

In type 2 diabetes (negative result). A trial of 71 participants with poorly controlled type 2 diabetes found that 600 mcg/day chromium picolinate for 4 months had no effect on total cholesterol, HDL, LDL, or triglycerides [28].

In PCOS (positive result). An 8-week trial in 40 women with PCOS found that 200 mcg/day chromium picolinate significantly decreased serum triglycerides (−19.2 vs +8.3 mg/dL) and total cholesterol (−15.3 vs −0.6 mg/dL) compared to placebo [55].

HDL and triglyceride effects (meta-analyses). Multiple meta-analyses have shown no significant changes in total cholesterol or LDL. However, some found chromium increases HDL by 1.73–4.64 mg/dL and decreases triglycerides by 11.71–26.57 mg/dL [37][38].

Beta-blocker-induced HDL reduction. Chromium may increase HDL cholesterol levels when these have been lowered by beta-blocker use [21].

Synthesis. Chromium supplementation does not meaningfully affect total cholesterol or LDL. There may be a modest positive effect on HDL and triglycerides, but the clinical significance is marginal.

Weight Loss and Body Composition

The hypothesis that chromium might aid weight loss is based on its role in insulin signaling: by amplifying insulin action, chromium could theoretically reduce glucose conversion to fat, increase protein synthesis, and enhance lean body mass. Some research suggests chromium may reduce food intake, hunger, and fat cravings [56].

2019 meta-analysis (21 trials, n=1,316). Adults with overweight or obesity (trial durations 9–24 weeks, chromium doses 200–1,000 mcg/day, primarily chromium picolinate) lost 0.75 kg more than placebo, with a 0.40 kg/m² BMI reduction and 0.68% body fat reduction. No significant effect on waist circumference (Tsang et al., Clin Obes, 2019) [57].

2013 Cochrane Review. Chromium picolinate produced statistically significant but clinically small reductions in body weight and fat percentage. The authors noted the effect was of "debatable clinical relevance" and evidence quality was low (Tian et al., Cochrane Database Syst Rev, 2013) [58].

Additional systematic reviews. Onakpoya et al. (2013) and Pittler et al. (2003) both found small but statistically significant weight loss effects of uncertain clinical relevance [59][60].

Synthesis. Chromium reduces body weight and fat percentage to a very small but statistically significant extent (approximately 0.75 kg over 9–24 weeks). This is well below what would be clinically meaningful. Chromium should not be relied upon as a weight loss supplement.

Cognitive Function

A small, placebo-controlled study examined whether 1,000 mcg daily of chromium picolinate improved learning, memory, or depression in older adults with early memory decline. Chromium did not improve primary outcomes. However, there was a slight reduction in semantic substitution errors (such as recalling "celery" instead of "cabbage") and some increased activation in certain brain regions on functional MRI (Krikorian et al., Nutritional Neuroscience, 2010) [63]. This remains the only published trial on chromium and cognition, and results are preliminary.

Recommended Dosing

Adequate Intakes (AIs)

The FNB established Adequate Intakes for chromium in 2001 [2]. These are based on observed intakes in healthy populations, not on a defined deficiency state:

Age Group	Male (mcg/day)	Female (mcg/day)
Birth to 6 months	0.2	0.2
7–12 months	5.5	5.5
1–3 years	11	11
4–8 years	15	15
9–13 years	25	21
14–18 years	35	24
19–50 years	35	25
51+ years	30	20
Pregnancy (14–18)	—	29
Pregnancy (19–50)	—	30
Lactation (14–18)	—	44
Lactation (19–50)	—	45

The FDA's Daily Value (DV) for chromium is 35 mcg for adults and children age 4 and older, updated in 2016 from the previous DV of 120 mcg [64].

No Tolerable Upper Intake Level (UL) has been established for chromium, due to insufficient long-term safety data. The FNB noted that caution may be warranted and that people with renal and liver disease might be susceptible to adverse effects from high intakes [2]. Doses below 200 mcg/day from supplements are generally considered safe [21].

Therapeutic Dosing by Indication

• For type 2 diabetes (adjunctive use): 200–1,000 mcg/day as chromium picolinate. Taking 500 mcg twice daily may decrease HbA1c after 2 months; 100 mcg twice daily may take up to 4 months [65]. Consult a doctor before use; medication adjustments may be needed.
• For reactive hypoglycemia: 200 mcg of chromium chloride daily for 3 months [43].
• For weight management: 200–400 mcg/day, though evidence of clinically significant benefit is weak [57][58].
• For general nutritional adequacy: Most multivitamins provide 35–120 mcg, sufficient to meet the AI [15].

Typical Dietary Intake

Estimates of chromium intake from diet in the US are approximately 25 mcg/day for women and 33 mcg/day for men [21]. A study of 8 men and 11 women found mean intakes of about 29 mcg/day for women and 54 mcg/day for men [66]. The mean chromium content per 2,000 kcal of 22 well-balanced diets was about 27 mcg (range: 17–47 mcg) [67]. A 2018 Italian assessment found median intake of approximately 57 mcg/day [68]. These findings suggest most people in developed countries meet the AIs through diet alone.

Calcium Interaction

Calcium carbonate may interfere with chromium absorption. It may be best to take chromium at a different time than calcium supplements, antacids, or large amounts of dairy [18].

Dietary Sources

Chromium is present in many foods, including meats, grain products, fruits, vegetables, nuts, spices, brewer's yeast, beer, and wine. However, chromium amounts vary widely depending on soil conditions, growing methods, and manufacturing processes [3][23][67]. For example, the chromium content in oatmeal can vary 50-fold [69]. Stainless steel equipment can also transfer chromium to food during processing and cooking [1][70].

Most dairy products and foods high in sugar are low in chromium [2][67]. High-sugar diets increase urinary chromium excretion, potentially worsening status [71].

Top Food Sources

Food (Serving Size)	Chromium (mcg)	% DV (35 mcg)
Brewer's yeast (2 oz)	50–60	143–171%
Calf liver (4 oz)	50–60	143–171%
Broccoli (½ cup)	11	31%
Grape juice (1 cup)	7.5–8	21–23%
Whole wheat English muffin (1)	3.6–4	10–11%
Ham (3 oz)	3.6	10%
Brewer's yeast (1 tbsp)	3.3	9%
Potatoes, mashed (1 cup)	3	9%
Garlic, dried (1 tsp)	3	9%
Orange juice (1 cup)	2–2.2	6%
Beef (3 oz)	2	6%
Turkey breast (3 oz)	1.7–2	5–6%
Whole wheat bread (2 slices)	2	6%
Lettuce, 1 wedge (~5 oz)	1.8	5%
Barbecue sauce (1 tbsp)	1.7	5%
Tomato juice (1 cup)	1.5	4%
Apple, with peel (1 medium)	1.4	4%
Green beans (½ cup)	1.1	3%
Red wine (5 oz)	1–13	3–37%
Banana (1 medium)	1	3%
Peanut butter (1 tbsp)	0.6	2%
Chicken breast (3 oz)	0.5	1%
Egg (1 medium)	0.2	1%

Sources: Anderson et al., Biol Trace Elem Res 1992; Cabrera-Vique et al., J Agric Food Chem 1997; Dattilo, Nutr Today 2003; NIH ODS [1][21][67][72].

Practical Notes

• Whole grains are a better source than refined grains. Refining wheat flour can reduce mineral content by up to 70% [67][73].
• Drinking water can contain chromium, especially hard water, though concentrations vary widely [21].
• Stainless steel cookware can add chromium to food through leaching [1][70].
• Vitamin C enhances absorption of chromium from food [1][18].
• High-sugar diets deplete chromium by increasing urinary losses [71].

Safety and Side Effects

Chromium is generally well tolerated at typical supplemental doses [1][21]. However, the safety profile warrants careful consideration, particularly at higher doses.

Reported Side Effects

At doses as low as 200–400 mcg per day, some patients have experienced [21]:

• Cognitive, perceptual, and motor dysfunction
• Headaches
• Insomnia and sleep disturbances
• Irritability and mood changes

Serious Adverse Effects (Case Reports)

At doses of 600–2,400 mcg/day, reports include anemia, thrombocytopenia, hemolysis, liver dysfunction (including one case of acute hepatitis at only 200 mcg chromium polynicotinate daily for 5 months [75]), kidney failure, and rhabdomyolysis. Causality has not been definitively established [21][74].

Worsened Insulin Sensitivity in Healthy People

Non-obese, non-diabetic adults given 1,000 mcg/day chromium picolinate for 16 weeks showed no benefits, and those who achieved the highest blood chromium levels experienced worsened insulin sensitivity [44]. This suggests chromium supplementation may be undesirable in healthy people who are not chromium deficient.

Allergic Reactions

Oral chromium can trigger allergic reactions in people with pre-existing chromate or leather contact allergy. Widespread skin rash has been reported (Fowler, Cutis, 2000) [76].

DNA Damage Concerns

Two preliminary in vitro studies suggested chromium picolinate might damage DNA [25][26]. These findings have not been confirmed in human studies. Trivalent chromium supplements at doses up to 1,000 mcg daily are generally considered safe based on human trial data [6].

Neurotransmitter Concerns with Picolinate Form

Because picolinic acid might affect neurotransmitter levels, chromium picolinate should be used with caution in people with depression, bipolar disorder, or psychosis [21]. A non-picolinate form (such as chromium glycinate) may be preferable in these populations.

Pregnancy and Lactation

Pregnant and lactating women should not take chromium doses above the established Adequate Intakes (29–30 mcg/day for pregnancy, 44–45 mcg/day for lactation) [21].

Drug Interactions

Insulin

Chromium may increase insulin sensitivity [27][62]. Taking chromium with insulin could increase hypoglycemia risk. Monitor blood sugar closely [77].

Metformin and Other Antidiabetes Medications

Chromium may have additive blood sugar-lowering effects with metformin, sulfonylureas, and other antidiabetes drugs, potentially increasing hypoglycemia risk [1][27][28]. Consult a healthcare provider before starting chromium.

Levothyroxine (Thyroid Medication)

Taking 1 mg of levothyroxine with 1 mg of chromium picolinate blunted levothyroxine absorption by 17% over 6 hours (John-Kalarickal et al., Thyroid, 2007) [78]. Take chromium picolinate at least 4 hours apart from levothyroxine.

Calcium Carbonate (Antacids)

Calcium carbonate may reduce chromium absorption. Take at different times [18].

Ascorbic Acid (Vitamin C)

Vitamin C enhances chromium absorption. While generally beneficial, this could theoretically increase chromium exposure when both supplements are taken together [1][18].

NSAIDs (Aspirin)

Aspirin and other prostaglandin inhibitors increase chromium absorption. No clinically significant adverse interaction has been documented [1].

Frequently Asked Questions

Does chromium help with diabetes?

Chromium picolinate at 200–1,000 mcg/day may produce modest reductions in fasting glucose and HbA1c (approximately 0.6% average) in some people with type 2 diabetes, particularly those with poor glycemic control. However, the evidence is mixed, and the American Diabetes Association does not recommend routine supplementation [32][34][41][42].

Is chromium effective for weight loss?

Chromium produces approximately 0.75 kg weight loss over 9–24 weeks — statistically significant but clinically insignificant [57][58].

Which form of chromium is best?

Chromium picolinate has the most clinical evidence. Chromium glycinate offers enhanced bioavailability. Both are better absorbed than chromium chloride [1][21][24].

Should healthy people take chromium supplements?

No evidence supports supplementation in healthy, non-diabetic individuals. One study found high-dose chromium (1,000 mcg/day) worsened insulin sensitivity in healthy adults [44]. Most people meet the AI through diet alone.

Is chromium safe?

At doses below 200 mcg/day, generally well tolerated. Higher doses (600–2,400 mcg/day) have been associated with case reports of liver dysfunction, kidney failure, and blood disorders. No UL has been established [2][21].

Is chromium really an essential nutrient?

This is debated. The US FNB considers it essential (2001), but EFSA concluded in 2014 that there is no convincing evidence of essentiality [2][7][8].

References

1. NIH Office of Dietary Supplements. "Chromium — Health Professional Fact Sheet." Updated March 29, 2024. https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/

2. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academy Press; 2001.

3. Vincent JB, Lukaski HC. "Chromium." Adv Nutr. 2018;9:505-506. https://pubmed.ncbi.nlm.nih.gov/30032227/

4. Eckhert CD. "Trace Elements." In: Ross AC, et al., eds. Modern Nutrition in Health and Disease. 11th ed. 2014:248-251.

5. Vincent JB. "Chromium." In: Marriott BP, et al., eds. Present Knowledge in Nutrition. 11th ed. 2020:457-465.

6. Grokipedia. "Chromium." https://grokipedia.com/page/Chromium

7. EFSA NDA Panel. "Scientific Opinion on Dietary Reference Values for chromium." EFSA Journal. 2014;12(10):3845. https://doi.org/10.2903/j.efsa.2014.3845

8. Vincent JB. "New evidence against chromium as an essential trace element." J Nutr. 2017;147:2212-2219. https://pubmed.ncbi.nlm.nih.gov/29021370/

9. Nielsen FH. "Summary: The metabolism, nutritional essentiality, and clinical importance of chromium." In: Vincent JB, ed. The Nutritional Biochemistry of Chromium (III). 2019:361-370.

10. Brown RO et al. "Chromium deficiency after long-term TPN." Dig Dis Sci. 1986;31:661-664. https://pubmed.ncbi.nlm.nih.gov/3087474/

11. Freund H et al. "Chromium deficiency during TPN." JAMA. 1979;241:496-498. https://pubmed.ncbi.nlm.nih.gov/104057/

12. Jeejeebhoy KN et al. "Chromium deficiency reversed by supplementation in a patient on TPN." Am J Clin Nutr. 1977;30:531-538. https://pubmed.ncbi.nlm.nih.gov/192066/

13. Fessler TA. "Trace elements in parenteral nutrition." Nutr Clin Pract. 2013;28:722-729. https://pubmed.ncbi.nlm.nih.gov/24163320/

14. Vanek VW et al. "A.S.P.E.N. position paper on parenteral multi-trace element products." Nutr Clin Pract. 2012;27:440-491. https://pubmed.ncbi.nlm.nih.gov/22730042/

15. Costello RB et al. "Chromium supplements in health and disease." In: Vincent JB, ed. The Nutritional Biochemistry of Chromium (III). 2019:219-259.

16. Nielsen FH. "Manganese, Molybdenum, Boron, Chromium, and Other Trace Elements." In: Present Knowledge in Nutrition. 10th ed. 2012:586-607.

17. Vincent JB. "Is the pharmacological mode of action of chromium(III) as a second messenger?" Biol Trace Elem Res. 2015;166:7-12. https://pubmed.ncbi.nlm.nih.gov/25820465/

18. Seaborn CD, Stoecker BJ. "Effects of antacid or ascorbic acid on tissue accumulation and urinary excretion of 51chromium." Nutr Res. 1990;10:1401-1407.

19. Anderson RA et al. "Stability and absorption of chromium histidinate complexes by humans." Biol Trace Elem Res. 2004;101:211-218. https://pubmed.ncbi.nlm.nih.gov/15564673/

20. Davies S et al. "Age-related decreases in chromium levels." Metabolism. 1997;46:469-473. https://pubmed.ncbi.nlm.nih.gov/9109854/

21. ConsumerLab. "Chromium Supplements Review." Accessed 2025. https://www.consumerlab.com/reviews/chromium-supplements/chromium/

22. Vincent JB. The Bioinorganic Chemistry of Chromium. John Wiley & Sons; 2013.

23. Swaroop A et al. "Benefits of chromium (III) complexes in animal and human health." In: Vincent JB, ed. The Nutritional Biochemistry of Chromium (III). 2019:251-278.

24. Gandia P et al. "A bioavailability study comparing Zn bis-glycinate vs. Zn gluconate." Int J Vitam Nutr Res. 2007;77(4):243-248. https://pubmed.ncbi.nlm.nih.gov/18271278/

25. Speetjens JK et al. "Chromium(III) tris(picolinate) cleaves DNA." Chem Res Toxicol. 1999;12(6):483-487. https://pubmed.ncbi.nlm.nih.gov/10368309/

26. Kareus SA et al. "Release of Cr(III) from Cr(III) picolinate upon metabolic activation." J Hazard Mater. 2001;84(2-3):163-174.

27. Anderson RA et al. "Elevated intakes of supplemental chromium improve glucose and insulin variables in T2D." Diabetes. 1997;46:1786-1791. https://pubmed.ncbi.nlm.nih.gov/9356027/

28. Paiva AN et al. "Beneficial effects of oral chromium picolinate on glycemic control in T2D." J Trace Elem Med Biol. 2015;32:66-72. https://pubmed.ncbi.nlm.nih.gov/26302914/

29. Kleefstra N et al. "Chromium has no effect in insulin-treated T2D." Diabetes Care. 2006;29(3):521-525. https://pubmed.ncbi.nlm.nih.gov/16505499/

30. Gunton JE et al. "Chromium does not improve glucose tolerance in impaired glucose tolerance." Diabetes Care. 2005;28:712-713. https://pubmed.ncbi.nlm.nih.gov/15735214/

31. Cefalu WT et al. "Metabolic response to chromium in T2D." Metabolism. 2010;59(5):755-762. https://pubmed.ncbi.nlm.nih.gov/19913842/

32. Costello RB et al. "Chromium supplements for glycemic control in T2D: limited evidence." Nutr Rev. 2016;74(7):455-468. https://pubmed.ncbi.nlm.nih.gov/27261273/

33. Wang ZQ, Cefalu WT. "Current concepts about chromium in T2D and insulin resistance." Curr Diab Rep. 2010;10(2):145-151. https://pubmed.ncbi.nlm.nih.gov/20425574/

34. Balk EM et al. "Effect of chromium supplementation on glucose metabolism and lipids." Diabetes Care. 2007;30(8):2154-2163. https://pubmed.ncbi.nlm.nih.gov/17519436/

35. Patal PC et al. "Meta-analysis of chromium picolinate on glucose and lipid profiles in T2D." Philipp J Intern Med. 2010;48:32-37.

36. Abdollahi M et al. "Effect of chromium on glucose and lipid profiles in T2D; a meta-analysis." J Pharm Pharm Sci. 2013;16:99-114. https://pubmed.ncbi.nlm.nih.gov/23683609/

37. Suksomboon N et al. "Efficacy and safety of chromium in diabetes." J Clin Pharm Ther. 2014;39(3):292-306. https://pubmed.ncbi.nlm.nih.gov/24635480/

38. Huang H et al. "Chromium supplementation for adjuvant treatment of T2D." Mol Nutr Food Res. 2018;62(1). https://pubmed.ncbi.nlm.nih.gov/28836373/

39. U.S. FDA. "Qualified Health Claims: Letters of Denial." 2005.

40. Trumbo PR, Ellwood KC. "Chromium picolinate and risk of T2D: FDA evidence review." Nutr Rev. 2006;64(8):357-363. https://pubmed.ncbi.nlm.nih.gov/16958312/

41. American Diabetes Association. "Standards of medical care in diabetes — 2010." Diabetes Care. 2010;33(S1):S11-61. https://pubmed.ncbi.nlm.nih.gov/20042772/

42. American Diabetes Association. "Foundations of care: 2015 position statement." Diabetes Care. 2015;38(S):S20-30. https://pubmed.ncbi.nlm.nih.gov/25537702/

43. Anderson RA et al. "Chromium supplementation: effects on glucose, insulin, and lipids." Metabolism. 1987;36(4):351-355.

44. Masharani U et al. "Chromium in non-obese non-diabetic subjects is associated with decline in insulin sensitivity." BMC Endocrine Disorders. 2012;12:31. https://doi.org/10.1186/1472-6823-12-31

45. National Heart, Lung, and Blood Institute. "Metabolic Syndrome." 2019.

46. Bai J et al. "Chromium exposure and metabolic syndrome over 23-year follow-up." Sci Rep. 2015;5:15606. https://pubmed.ncbi.nlm.nih.gov/26493398/

47. Iqbal N et al. "Chromium picolinate does not improve metabolic syndrome features." Metab Syndr Relat Disord. 2009;7(2):143-150. https://pubmed.ncbi.nlm.nih.gov/19422140/

48. Nussbaumerova B et al. "Chromium supplementation in metabolic syndrome with impaired glucose tolerance." Biol Trace Elem Res. 2018;183:192-199. https://pubmed.ncbi.nlm.nih.gov/28871475/

49. Kim HN et al. "Zinc, magnesium, and chromium supplementation in metabolic syndrome." J Trace Elem Med Biol. 2018;48:166-171. https://pubmed.ncbi.nlm.nih.gov/29773203/

50. Goldrat O, Delbaere A. "PCOS: update and diagnostic approach." Clin Biochem. 2018;62:24-31. https://pubmed.ncbi.nlm.nih.gov/29885302/

51. Fazelian S et al. "Chromium and PCOS: systematic review and meta-analysis." J Trace Elem Med Biol. 2017;42:92-96. https://pubmed.ncbi.nlm.nih.gov/28595797/

52. Tang XL et al. "Chromium in women with PCOS: systematic review." J Obstet Gynaecol Res. 2018;44(1):134-143. https://pubmed.ncbi.nlm.nih.gov/29094433/

53. Heshmati J et al. "Chromium on insulin resistance in PCOS." Horm Metab Res. 2018;50(3):193-200. https://pubmed.ncbi.nlm.nih.gov/29523005/

54. Maleki V et al. "Chromium does not improve weight or metabolic variables in PCOS." Nutr Res. 2018;56:1-10. https://pubmed.ncbi.nlm.nih.gov/30055770/

55. Jamilian M et al. "Chromium supplementation in infertile PCOS women." Biol Trace Elem Res. 2018;185(1):48-55. https://pubmed.ncbi.nlm.nih.gov/29464598/

56. Anton SD et al. "Effects of chromium picolinate on food intake and satiety." Diabetes Technol Ther. 2008;10(5):405-412. https://pubmed.ncbi.nlm.nih.gov/18715218/

57. Tsang C et al. "Chromium supplementation on anthropometric indices in overweight/obesity." Clin Obes. 2019;9(4):e12313. https://pubmed.ncbi.nlm.nih.gov/31136084/

58. Tian H et al. "Chromium picolinate for overweight or obese adults." Cochrane Database Syst Rev. 2013;(11):CD010063. https://pubmed.ncbi.nlm.nih.gov/24293292/

59. Onakpoya I et al. "Chromium in overweight and obesity: systematic review." Obes Rev. 2013;14(6):496-507. https://pubmed.ncbi.nlm.nih.gov/23495911/

60. Pittler MH et al. "Chromium picolinate for reducing body weight." Int J Obes. 2003;27(4):522-529. https://pubmed.ncbi.nlm.nih.gov/12664086/

61. Kaats GR et al. "Chromium picolinate supplementation on body composition." Cur Ther Res. 1996;57(10):747-756.

62. Martin J et al. "Chromium picolinate attenuates weight gain and increases insulin sensitivity in T2D." Diabetes Care. 2006;29(8):1826-1832. https://pubmed.ncbi.nlm.nih.gov/16873787/

63. Krikorian R et al. "Improved cognitive-cerebral function in older adults with chromium supplementation." Nutritional Neuroscience. 2010;13(3):116-122.

64. U.S. FDA. "Food Labeling: Revision of Nutrition and Supplement Facts Labels." 2016.

65. Ravina A et al. "Clinical use of chromium(III) in diabetes treatment." Harefuah. 1993;125(5-6):142-145.

66. Anderson RA et al. "Dietary chromium intake." Biol Trace Elem Res. 1992;32:117-121. https://pubmed.ncbi.nlm.nih.gov/1375078/

67. Anderson RA et al., Biol Trace Elem Res 1992; Dattilo AM, Nutr Today 2003.

68. Filippini T et al. "Dietary intake of chromium in Northern Italy." J Trace Elem Med Biol. 2018;50:508-517. https://pubmed.ncbi.nlm.nih.gov/30262289/

69. Vincent JB. "Chromium: Properties and Determination." In: Encyclopedia of Food and Health. 2016:114-118.

70. Kuligowski J, Halperin KM. "Stainless steel cookware as a significant source of chromium." Arch Environ Contam Toxicol. 1992;23(2):211-215. https://pubmed.ncbi.nlm.nih.gov/1514844/

71. Kozlovsky AS et al. "Effects of diets high in simple sugars on urinary chromium losses." Metabolism. 1986;35(6):515-518. https://pubmed.ncbi.nlm.nih.gov/3713513/

72. Cabrera-Vique C et al. "Chromium in beer, wine, and fruit juices." J Agric Food Chem. 1997;45(5):1808-1811.

73. Hamilton EM et al. "Chromium speciation in foodstuffs." Food Chem. 2018;250:105-112. https://pubmed.ncbi.nlm.nih.gov/29412899/

74. Vincent JB. "Toxicity of chromium picolinate as a nutritional supplement." Sports Med. 2003;33(3):213-230. https://pubmed.ncbi.nlm.nih.gov/12656641/

75. Lanca S et al. "Acute hepatitis from chromium polynicotinate." Eur J Intern Med. 2002;13(8):518-520.

76. Fowler JF Jr. "Systemic contact dermatitis from oral chromium picolinate." Cutis. 2000;65(2):116. https://pubmed.ncbi.nlm.nih.gov/10696569/

77. Landman GW et al. "Chromium does not belong in the diabetes treatment arsenal." World J Diabetes. 2014;5(2):160-164. https://pubmed.ncbi.nlm.nih.gov/24748928/

78. John-Kalarickal J et al. "Medications which decrease levothyroxine absorption." Thyroid. 2007;17(8):763-765. https://pubmed.ncbi.nlm.nih.gov/17725434/